Magnesium-L-threonate Ameliorates Cognitive Deficit by Attenuating Adult Hippocampal Neurogenesis Impairment in a Mouse Model of Alzheimer's Disease.
Study Goal
The researchers aimed to determine if magnesium-L-threonate (MgT) could improve cognitive deficits in an Alzheimer's disease mouse model by enhancing adult hippocampal neurogenesis and to explore the underlying mechanisms.
Results Summary
MgT treatment improved memory impairment in AD mice, increased newborn neuron markers (BrdU/doublecortin), and elevated doublecortin expression. These effects were linked to ERK/CREB activation and were reversed by an ERK inhibitor.
Population
APPswe/PS1dE9 transgenic mice (Alzheimer's disease model).
Effective Dosage
Different doses (specific amounts not stated).
Duration
Not specified.
Interactions
None mentioned.
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
magnesium-L-threonate (MgT) | decrease | memory impairment | APPswe/PS1dE9 mice | - | attenuated | #1 |
magnesium-L-threonate (MgT) | increase | Brdu/doublecortin labeled newborn neurons | APPswe/PS1dE9 mice | - | increased | #2 |
magnesium-L-threonate (MgT) | increase | doublecortin expression levels | APPswe/PS1dE9 mice | - | significantly increased | #3 |
magnesium-L-threonate (MgT) | increase | ratios of p-ERK/ERK | APPswe/PS1dE9 mice | - | increased | #4 |
magnesium-L-threonate (MgT) | increase | ratios of p-CREB/CREB | APPswe/PS1dE9 mice | - | increased | #5 |
PD0325901 supplementation | decrease | effects of MgT treatment | APPswe/PS1dE9 mice | - | markedly reversed | #6 |
Impaired adult hippocampal neurogenesis is a key pathological mechanism contributing to memory deficits in Alzheimer's disease (AD). Recent studies have shown that elevating magnesium levels promotes neurogenesis by enhancing the neuronal differentiation of adult neural progenitor cells in vitro. Therefore, this in vivo study aims to determine if magnesium-L-threonate (MgT) can ameliorate cognitive deficit of AD mice by attenuating adult hippocampal neurogenesis impairment and to reveal the underlying mechanisms. APPswe/PS1dE9 mice were treated with different doses of MgT and ERK inhibitor PD0325901. The memory ability of each mouse was recorded by Morris Water Maze test. After cognitive test, hippocampus tissues were collected to measure the proportion of BrdU/doublecortin double-labeled cells using the flow cytometry test and assess the expression of doublecortin using PCR and Western blot. Furthermore, the activations of CREB, ERK, P38 and JNK were measured by Western blot to identify the involved mechanisms. The cognitive test confirmed that MgT treatment attenuated the memory impairment of APPswe/PS1dE9 mice. Flow cytometry test showed that Brdu/doublecortin labeled newborn neurons gradually increased following MgT administration. In line with the flow cytometry results, Western blot and PCR confirmed that MgT administration significantly increased doublecortin expression levels. Furthermore, the ratios of p-ERK/ERK and p-CREB/CREB increased with MgT elevation. In addition, these effects of MgT treatment were markedly reversed by PD0325901 supplementation. In conclusion, MgT treatment improved cognitive decline by ameliorating adult hippocampal neurogenesis impairment in this AD model, possibly via ERK/CREB activation.